Olaparib plus abiraterone versus placebo plus abiraterone in metastatic castration-resistant prostate cancer (PROpel): final prespecified overall survival results of a randomised, double-blind, phase 3 trial
Centre Hospitalier de l’Université de Montréal · Salford Royal NHS Foundation Trust · +17 more institutions
Indexed incrossrefpubmed
Abstract
No abstract available for this paper.
Citation impact
283
total citations
- FWCI
- 68.58
- Percentile
- 100%
- References
- 27
Citations per year
Authors
19Topics & keywords
Topics
Keywords
- Abiraterone
- Prostate cancer
- Medicine
- Placebo
- Olaparib
- Urology
- Abiraterone acetate
- Internal medicine
UN Sustainable Development Goals
- Good health and well-being
No related works found for this paper.
Funding
- AAmgen
- BSBristol-Myers Squibb
- ELEli Lilly and Company
- PPfizer
- AAstraZeneca
- MMerck
- SSanofi
- GSGilead Sciences
- EEndocyte
- EExelixis
- CPConstellation Pharmaceuticals
- BBeiGene
- AAAdvanced Accelerator Applications
- IInvitae
- APAstellas Pharma
- IIpsen
- BNBavarian Nordic
- GGenentech
- ESEMD Serono
- MSMerck Sharp and Dohme
- JPJanssen Pharmaceuticals